Smart Phone based single lead ECGs versus traditional ambulatory Holter monitoring for definite diagnosis of cardiac arrhythmias in patients with symptomatic palpitations: a randomised controlled trial

Western Sydney Local Health District (WSLHD)0 个研究点目标入组 80 人开始时间: 2019年5月29日最近更新: 2020年2月3日

试验速览

暂无简介。

•1.Patients aged greater than or equal to 18 years;
•2.Symptomatic palpitations in whom initial 12 lead ECG has failed to detect arrhythmia.
•3.At least two episodes of palpitations in the preceding 6 months;
•4.Have a smartphone and/or a smartwatch capable of running the Alivecor application.

•Patients will be excluded if they are:
•1.are unable or unwilling to provide informed consent;
•2.Patients in whom palpitations are known to have a physiologic such as anaemia, thyroid dysfunction, heart failure, or women who are pregnant or breast feeding;
•3.Concomitant illness, physical impairment or mental condition which in the opinion of the study team/ primary care physician could interfere with the conduct of the study including outcome assessments;
•4.Inability or unwillingness to provide written informed consent;
•5.Unable to complete study procedures;
•6.Medical illness with anticipated life expectancy < 3 months;
•7.Responsible primary care or other responsible physician believes it is not appropriate to participate in the study.
•8.poor baseline sECG recording;
•9.Lack of understanding of how to record sECG after initial consultation.
•10.Do not have a smartphone and/or a smartwatch that is compatible with running the Alivecor application.

发起方

Western Sydney Local Health District (WSLHD)